PRLHR - Prolactin-releasing peptide receptor | Elisa - Clia - Antibody - Protein

Background:

The Prolactin-Releasing Peptide Receptor (PRLHR) is a G protein-coupled receptor (GPCR) that responds to prolactin-releasing peptide (PrRP), a neuropeptide involved in various physiological processes. PRLHR is a GPCR that mediates the effects of prolactin-releasing peptide (PrRP), a neuropeptide primarily found in the hypothalamus and other brain regions. PRLHR is expressed in the central nervous system, particularly in the hypothalamus, where it regulates neuroendocrine function, energy homeostasis, and stress responses. PRLHR is activated by PrRP, a 31-amino acid peptide that is derived from the prepro-PrRP precursor. In summary, the Prolactin-Releasing Peptide Receptor (PRLHR) is a GPCR that mediates the effects of prolactin-releasing peptide (PrRP) in various physiological processes, including neuroendocrine regulation, energy homeostasis, and stress responses. Dysregulation of PRLHR signaling is implicated in metabolic disorders, neurological disorders, and psychiatric disorders, making PRLHR a potential therapeutic target for these conditions.

Structural Features:

• PRLHR is a typical GPCR with seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus.
• Upon ligand binding, conformational changes occur in the receptor, leading to activation of downstream signaling pathways.

Physiological Functions:

• Neuroendocrine Regulation: PRLHR signaling regulates the release of various hormones, including prolactin, corticotropin-releasing hormone (CRH), and adrenocorticotropic hormone (ACTH), influencing stress responses, reproductive function, and metabolism.
• Energy Homeostasis: PRLHR activation modulates feeding behavior, energy expenditure, and body weight regulation, implicating the receptor in metabolic disorders such as obesity and diabetes.
• Stress Responses: PRLHR signaling is involved in the regulation of stress responses, anxiety, and mood states, influencing emotional behavior and psychiatric disorders.

Clinical Implications:

• Metabolic Disorders: Dysregulation of PRLHR signaling is associated with metabolic disorders such as obesity, insulin resistance, and dyslipidemia.
• Neurological Disorders: Altered PRLHR expression or function is implicated in neurological disorders such as depression, anxiety disorders, and schizophrenia.

Therapeutic Potential:

• Obesity Treatment: Modulation of PRLHR signaling pathways may offer therapeutic strategies for the treatment of obesity and related metabolic disorders.
• Psychiatric Disorders: Targeting PRLHR signaling could be explored as a potential treatment approach for psychiatric disorders such as depression and anxiety.
• Endocrine Disorders: Manipulation of PRLHR activity may have therapeutic implications for endocrine disorders involving dysregulated hormone secretion.